Table of Contents
Key Points
- Tazi’s 8.19% stake gained $8.01 million in 2025, reversing last year’s losses and reinforcing her influence on the Casablanca Bourse.
- The pharmaceutical firm’s stock has surged 14.6% this year, lifting its valuation past $760 million and rewarding investors with strong returns.
- Under CEO Lamia Tazi, Sothema’s expansion and market gains strengthen its position as a key player in North Africa’s pharmaceutical industry.
Lamia Tazi, a leading figure in Morocco’s pharmaceutical industry, has seen a significant increase in the market value of her investment in Marocaine Ste de Therapeutique (Sothema), thanks to a recent surge in Sothema’s share price on the Casablanca Bourse.
Lamia Tazi’s stake surges by $8.01 million
Tazi holds an 8.19 percent stake in Sothema, equivalent to 589,658 shares. The recent upswing in stock price has added MAD79.6 million ($8.01 million) to her stake since the start of 2025, reversing last year’s decline and reinforcing her position as one of the most influential investors on the Casablanca Bourse.
In 2024, her stake had dropped by $2.98 million, falling from MAD575.38 million ($58.31 million) to MAD559.65 million ($55.33 million) due to broader market pressures. The latest rebound not only wipes out those losses but also reflects renewed investor confidence in Sothema’s long-term growth.
Sothema’s market capitalization tops $767 million
Sothema, Morocco’s healthcare company, produces about 60 million pharmaceutical units each year and partners with 35 multinational laboratories. Its products are distributed across Europe, the Maghreb, Sub-Saharan Africa, and the Persian Gulf, reflecting its key role in the region’s healthcare supply chain.
Since the start of the year, Sothema’s stock has gained 14.6 percent on the Casablanca bourse, pushing its market value past $760 million. Shares have risen from MAD925 ($93.10) on Jan. 1 to MAD1,060 ($106.68) at the time of reporting, delivering strong returns for investors.
Strategic leadership fuels growth
The recent rally has boosted the value of Sothema CEO and chairperson Lamia Tazi’s 8.19 percent stake from MAD545.43 million ($54.9 million) on Jan. 1 to MAD625.04 million ($62.91 million), reinforcing her position among the Casablanca Bourse’s top investors.
This underscores investor confidence in Tazi’s leadership as she drives Sothema’s expansion and operational growth. Her growing fortune reflects the company’s increasing presence in key international markets, strengthening its position as a leading player in North Africa’s pharmaceutical industry.
